Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex

A-CD137, lymphocyte technology, applied in the field of immunology, can solve the problems such as the need to improve the amplification and activation effect, the long fragment, and the difficulty in obtaining a large number of LAK cells

Active Publication Date: 2013-08-14
杭州中赢生物医疗科技有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The number of LAK cells is directly related to the curative effect. The problem in the treatment is that it is very difficult to obtain a large number of LAK cells
[0004] CN201110075736.1. discloses a method for amplifying and activating lymphocytes using CD8α-interleukin 21-CD137 complex, but the effect of expansion and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex
  • Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex
  • Method for amplifying and activating lymphocyte cells by CD 8 alpha-interleukin 21 fragment-CD137 complex

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Transmembrane interleukin 21 fragment-CD137 complex expands LAK cells in vitro.

[0046] NK cells from healthy donors were cultured in RPMI1640 supplemented with 10% human serum. K562 cells expressing transmembrane interleukin-21-CD137 complex (control) and K562 cells expressing transmembrane interleukin-21 fragment-CD137 complex (irradiated, 100Gy) and low-dose interleukin-2 were added to the culture medium and cultured for 7 days . Centrifuge after 7 days, resuspend with an equal amount of culture medium, add irradiated K562 cells, and culture for another 7 days ( figure 1 ). High-dose interleukin-2 (200 units / ml) was also used as a control group. Such as figure 2 As shown in A, the number of LAK cells was significantly increased under the joint action of transmembrane interleukin-21 fragment-CD137 complex and low-dose interleukin-2. An increase in cell number can be measured by the insertion of thymidine. Cells were cultured for 12 hours after thymidine inserti

Embodiment 2

[0048] Transmembrane interleukin 21 fragment-CD137 complex expands unpurified peripheral blood lymphocytes

[0049] The transmembrane interleukin 21 fragment-CD137 complex can expand not only purified NK cells, but also unpurified lymphocytes. PBM from healthy donors were cultured in RPMI1640 supplemented with 10% human serum. K562 cells expressing transmembrane interleukin-21-CD137 complex (control) and K562 cells expressing transmembrane interleukin-21 fragment-CD137 complex (irradiated, 100Gy) and low-dose interleukin-2 were added to the culture medium and co-cultured for 7 sky. Centrifuged after 7 days, resuspended with an equal amount of culture medium, added K562 cells irradiated by 100Gy, and cultured for another 7 days ( figure 1 ). High-dose interleukin-2 (200 units / ml) was also used as a control group. Such as figure 2 As shown in B, the number of LAK cells was significantly increased under the joint action of transmembrane interleukin-21 fragment-CD137 complex

Embodiment 3

[0052] Detection of Telomerase Activity and STAT3 Phosphorylation in LAK Cells

[0053] The amplified cells were disrupted by repeated freezing and thawing with liquid nitrogen, centrifuged at 10,000 g, and the supernatant was taken, and the telomerase activity of the amplified LAK cells was detected by the TRAP method. 50 μl TRAP system contains 20 mmol / L Tris-HCl (pH8.3), 1.5 mmol / L MgCl, 63 mmol / L, KCl, 0.005% Tween-20, 1 mmol / L EDTA, 50 Millimolar / L dNTP, 0.1 μg tS, 1 μg T4, 0.1 mg / ml bovine serum albumin, 1-2 μl CHAPS, cell extract (including 6 μg) protein, 0.2-0.4 μl [α- 32 P]dGTP. Reaction conditions: 10 minutes at 23°C, 3 seconds at 94°C, add Taq enzyme, 30 seconds at 94°C, 30 seconds at 50°C, 1.5 minutes at 72°C, 27 cycles of amplification, take 25 μl of product for 15% PAGE gel electrophoresis. Autoradiography on X-ray film after PAGE gel electrophoresis for 8 hours to more than two days. Compared with before amplification, the high dose of interleukin 2

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of immunology and specifically relates to a method for amplifying and activating natural killer (NK) cells to become lymphokine activated killer (LAK) cells through the action of a CD 8 alpha-interleukin 21 fragment-CD137 complex. The method disclosed by the invention has the advantages that compared with existing similar complexes, the capability of amplifying and activating the lymphocyte cells is stronger and the efficiency is higher through the CD 8 alpha-interleukin 21 fragment-CD137 complex. The method disclosed by the invention has broad prospects in the aspect of immunotherapy.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner 杭州中赢生物医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products